Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

NCT01235221 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: BIIB041 (Fampridine-SR)

Sponsor

Biogen

Collaborators

[object Object]